Cargando…

Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial

INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xuelian, Huang, Shaohui, Wang, Yusi, Peng, Qun, Li, Weixin, Zou, Yingying, Han, Zelong, Cai, Jianqun, Luo, Yuchen, Ye, Yaping, Li, Aimin, Bai, Yang, Chen, Ye, Liu, Side, Li, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508268/
https://www.ncbi.nlm.nih.gov/pubmed/36455222
http://dx.doi.org/10.14309/ajg.0000000000001914
_version_ 1785107497681420288
author Gao, Xuelian
Huang, Shaohui
Wang, Yusi
Peng, Qun
Li, Weixin
Zou, Yingying
Han, Zelong
Cai, Jianqun
Luo, Yuchen
Ye, Yaping
Li, Aimin
Bai, Yang
Chen, Ye
Liu, Side
Li, Yue
author_facet Gao, Xuelian
Huang, Shaohui
Wang, Yusi
Peng, Qun
Li, Weixin
Zou, Yingying
Han, Zelong
Cai, Jianqun
Luo, Yuchen
Ye, Yaping
Li, Aimin
Bai, Yang
Chen, Ye
Liu, Side
Li, Yue
author_sort Gao, Xuelian
collection PubMed
description INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) methods for the treatment of rectal NET ≤10 mm. METHODS: A randomized noninferiority trial comparing mEMR-C and ESD was conducted. The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on. Subgroup analyses and follow-up were also performed. RESULTS: Ninety patients were enrolled, and 79 patients with pathologically confirmed rectal NET were finally analyzed, including 38 cases of mEMR-C and 41 cases of ESD. Histological complete resection rate was 97.4% in the mEMR-C group and 92.7% in the ESD group. The noninferiority of mEMR-C compared with that of ESD was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, −3.3% to 12.2%; P = 0.616). En bloc resection and successful removal of rectal NET were achieved in all patients. Advantages of mEMR-C over ESD included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, P < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, P < 0.05). Postoperative complications were recorded in 4 patients who received mEMR-C and 2 patients in the ESD group (11.5% vs 4.9%, P = 0.509), which were all well managed using endoscopy. Similar findings were observed when subgroup analysis was performed. DISCUSSION: mEMR-C is noninferior to ESD with a similar complete resection rate. In addition, mEMR-C had shorter procedure duration time and lower hospitalization costs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03982264.
format Online
Article
Text
id pubmed-10508268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-105082682023-09-20 Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial Gao, Xuelian Huang, Shaohui Wang, Yusi Peng, Qun Li, Weixin Zou, Yingying Han, Zelong Cai, Jianqun Luo, Yuchen Ye, Yaping Li, Aimin Bai, Yang Chen, Ye Liu, Side Li, Yue Am J Gastroenterol Article INTRODUCTION: Although recent guidelines recommend endoscopic resection of rectal neuroendocrine tumors (NET) ≤10 mm, there is no consensus on which endoscopic modality should be performed. We aimed to compare the safety and efficacy of modified cap-assisted endoscopic mucosal resection (mEMR-C) and endoscopic submucosal dissection (ESD) methods for the treatment of rectal NET ≤10 mm. METHODS: A randomized noninferiority trial comparing mEMR-C and ESD was conducted. The primary outcome was the histological complete resection rate; the secondary outcomes included en bloc resection rate, operation time, complications, and so on. Subgroup analyses and follow-up were also performed. RESULTS: Ninety patients were enrolled, and 79 patients with pathologically confirmed rectal NET were finally analyzed, including 38 cases of mEMR-C and 41 cases of ESD. Histological complete resection rate was 97.4% in the mEMR-C group and 92.7% in the ESD group. The noninferiority of mEMR-C compared with that of ESD was confirmed because the absolute difference was 4.7% (2-sided 90% confidence interval, −3.3% to 12.2%; P = 0.616). En bloc resection and successful removal of rectal NET were achieved in all patients. Advantages of mEMR-C over ESD included shorter operation time (8.89 ± 4.58 vs 24.8 ± 9.14 minutes, P < 0.05) and lower hospitalization cost ($2,233.76 ± $717.70 vs $2,987.27 ± $871.81, P < 0.05). Postoperative complications were recorded in 4 patients who received mEMR-C and 2 patients in the ESD group (11.5% vs 4.9%, P = 0.509), which were all well managed using endoscopy. Similar findings were observed when subgroup analysis was performed. DISCUSSION: mEMR-C is noninferior to ESD with a similar complete resection rate. In addition, mEMR-C had shorter procedure duration time and lower hospitalization costs. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03982264. Wolters Kluwer 2022-12 2022-08-23 /pmc/articles/PMC10508268/ /pubmed/36455222 http://dx.doi.org/10.14309/ajg.0000000000001914 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Gao, Xuelian
Huang, Shaohui
Wang, Yusi
Peng, Qun
Li, Weixin
Zou, Yingying
Han, Zelong
Cai, Jianqun
Luo, Yuchen
Ye, Yaping
Li, Aimin
Bai, Yang
Chen, Ye
Liu, Side
Li, Yue
Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title_full Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title_fullStr Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title_full_unstemmed Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title_short Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial
title_sort modified cap-assisted endoscopic mucosal resection versus endoscopic submucosal dissection for the treatment of rectal neuroendocrine tumors ≤10 mm: a randomized noninferiority trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508268/
https://www.ncbi.nlm.nih.gov/pubmed/36455222
http://dx.doi.org/10.14309/ajg.0000000000001914
work_keys_str_mv AT gaoxuelian modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT huangshaohui modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT wangyusi modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT pengqun modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT liweixin modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT zouyingying modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT hanzelong modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT caijianqun modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT luoyuchen modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT yeyaping modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT liaimin modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT baiyang modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT chenye modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT liuside modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial
AT liyue modifiedcapassistedendoscopicmucosalresectionversusendoscopicsubmucosaldissectionforthetreatmentofrectalneuroendocrinetumors10mmarandomizednoninferioritytrial